A randomized phase ii study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (Abraxane) in patients with extensive-stage small cell lung cancer

Oncologist

Volumn 20, Issue 2, 2015, Pages 105-106

  Grilley Olson, Juneko E ^a   Keedy, Vicki L ^b   Sandler, Alan ^c   Moore, Dominic T ^a   Socinski, Mark A ^d   Stinchcombe, Thomas E ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; NANOPARTICLE; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT;

AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SMALL CELL LUNG CANCER; THROMBOCYTOPENIA; VOMITING; ADULT; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ALBUMIN-BOUND PACLITAXEL; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NANOPARTICLES; NEOPLASM STAGING; PACLITAXEL; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84922732000     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0327     Document Type: Article

References (1)

1. Makoto Maemondo, Akira Inoue, Shunichi Sugawara et al. Randomized Phase II Trial Comparing Carboplatin Plus Weekly Paclitaxel and Docetaxel Alone in Elderly Patients With Advanced Non-Small Cell Lung Cancer: North Japan Lung Cancer Group Trial 0801. The Oncologist 2014;19:352-353.